Multiple Murine Double Minute Gene 2 (MDM2) Proteins Are Induced by Ultraviolet Light*

Leslie J. SaucedoDagger , Cena D. Myers§, and Mary Ellen Perry

From the Program in Cell and Molecular Biology and the Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
REFERENCES

The mdm2 (murine double minute 2) oncogene encodes several proteins, the largest of which (p90) binds to and inactivates the p53 tumor suppressor protein. Multiple MDM2 proteins have been detected in tumors and in cell lines expressing high levels of mdm2 mRNAs. Here we show that one of these proteins (p76) is expressed, along with p90, in wild-type and p53-null mouse embryo fibroblasts, indicating that it may have an important physiological role in normal cells. Expression of this protein is induced, as is that of p90, by UV light in a p53-dependent manner. The p76 protein is synthesized via translational initiation at AUG codon 50 and thus lacks the N terminus of p90 and does not bind p53. In cells, p90 and p76 can be synthesized from mdm2 mRNAs transcribed from both the P1 (constitutive) and P2 (p53-responsive) promoters. Site-directed mutagenesis reveals that these RNAs give rise to p76 via internal initiation of translation. In addition, mdm2 mRNAs lacking exon 3 give rise to p76 exclusively, and such mRNAs are induced by p53 in response to UV light. These data indicate that p76 may be an important product of the mdm2 gene and a downstream effector of p53.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
REFERENCES

The mdm2 oncogene is a determinant of embryogenesis (1, 2), tumorigenesis (3, 4), and cell cycle progression (5, 6). The effects of MDM2 on these processes depend, in part, on its ability to inactivate the p53 tumor suppressor protein. For example, mice with a homozygous deletion of the mdm2 gene die during embryogenesis, and this deficiency is rescued if p53 is also deleted (1, 2). In human tumors, the homologue of MDM2 is overexpressed most often in the subset lacking inactivating mutations in the p53 gene (7). Thus, high levels of MDM2 may be redundant with mutational inactivation of p53. Following exposure of cells to gamma -radiation, MDM2 inactivates the G1 block mediated by p53 (5). In some cell types, MDM2 can inhibit apoptosis mediated by p53 (8). MDM2 binds to p53, inhibiting the transcriptional activation function of p53 (3, 9) and stimulating degradation of p53 (10, 11). Recently, MDM2 has been shown to bind to another tumor suppressor protein, p19ARF (12, 13). The ability of MDM2 to stimulate degradation of p53 is inhibited by p19ARF, indicating that the interaction of p19ARF and MDM2 may be an important determinant of cell cycle progression.

In addition to interacting with p53 and p19ARF, MDM2 binds to and alters the function of other proteins that regulate cell division. For example, overexpression of MDM2 stimulates the activity of the E2F transcription factor (14) and reverses an arrest in the cell cycle mediated by either the retinoblastoma protein (15) or a related protein, p107 (6). These effects of MDM2 do not depend on the presence of p53. Further evidence for p53-independent functions of MDM2 was provided by Lundgren et al. (4), who generated mice expressing high levels of MDM2 in the mammary gland. The mammary epithelial cells of these mice developed polyploidy, and this effect of MDM2 was also seen in mice lacking p53. Mammary tumors arose in mice overexpressing mdm2, but the dependence on p53 was not measured since mice lacking p53 die before mammary tumors would have developed. Sigalis et al. (16) found that alternatively spliced mdm2 mRNAs were overexpressed in some human tumors. Introduction of these mRNAs into NIH3T3 cells resulted in morphological transformation, even though a subset of them encoded MDM2 proteins that could not bind p53. Therefore, some of the oncogenic effects of MDM2 are independent of p53.

Several MDM2 proteins are detectable in cells overexpressing MDM2, including human tumor cells and transformed murine cell lines (17, 18). Olson et al. (17) hypothesized that these proteins arise through alternative splicing, proteolytic processing, or post-translational modification. It has not been clear whether these proteins arise through mechanisms used in the normal regulation of mdm2 expression. Multiple MDM2 proteins can be translated from single mRNAs in rabbit reticulocyte lysates, indicating that internal initiation may be a mechanism whereby multiple MDM2 proteins are expressed in cells (19). In fact, there is evidence that enhanced translation accounts for the overexpression of multiple MDM2 proteins in some human tumors (18). In the DM3T3 cell line, in which the mdm2 gene is amplified, multiple MDM2 proteins and mRNAs are expressed (17, 20). The most abundant protein in DM3T3 cells (p90) is the well characterized mdm2 gene product that binds to p53 and inhibits its function (3, 9, 10, 11). The second most abundant protein (p76) does not bind p53 (17, 19), but does bind p19ARF (13). The primary structure and source of p76 have not been established.

Here we show that p76 is a bona fide product of the mdm2 gene, as it is expressed in normal wild-type MEFs,1 but not in mdm2-null fibroblasts. Expression of p76 is induced by UV light in a p53-dependent manner. Using epitope mapping and site-directed mutagenesis, we show that p76 appears to be the product of translational initiation at codon 50 (AUG). Both internal initiation and alternate splicing can give rise to p76 in cells. The p53-responsive internal promoter of mdm2 is induced by UV light, and a fraction of the induced RNA is spliced such that it lacks exon 3 and the first two AUG codons. In this alternatively spliced mRNA, AUG codon 50 (referred to hereafter as AUG 50) is the first initiation codon. We provide evidence that the increase in this alternatively spliced mRNA accounts for the induction of p76 expression in response to UV light. Identification and characterization of p76 are important because it is likely to share some oncogenic functions with p90.

    EXPERIMENTAL PROCEDURES

Cell Culture-- Wild-type MEFs were obtained from Arnold J. Levine. MEFs lacking p53 or both p53 and MDM2 were provided by Guillermina Lozano (21). All three strains of fibroblasts were derived from 14-day-old embryos with a mixed Sv129 × C57BL/6 genotype. DM3T3 cells are transformed murine fibroblasts that contain amplified copies of the mdm2 gene (20). C127 is a nontransformed murine cell line expressing wild-type p53 (22). The (10)3 cell line lacks p53 and was derived from 14-day-old embryos of BALB/c mice (23). COS-1 cells are African green monkey kidney cells expressing the large T-antigen of simian virus 40 (24). All cells were cultured in Dulbecco's modified Eagle's medium plus 10% fetal calf serum (Summit).

Plasmids and Mutagenesis-- Several plasmids expressing mdm2 were used to generate MDM2 proteins in reticulocyte lysates. pGEM1F, pGEM1X2, and pGEM1B (19) were kindly provided by Moshe Oren. pGEM1F expresses an mRNA containing exons 1-12; pGEM1X2 contains exons 2-12; and pGEM1B contains part of exon 3 and exons 4-12. Derivatives of pGEM1F were made that contain mutations at either ATG 50 (F50) or ATG 62 (F62) and at both ATGs 50 and 62 (F50,62). The template for site-directed mutagenesis of the mdm2 coding region was pGEM1X2 (19). Single- or double-base changes were achieved using two oligonucleotides, both of which contained the desired base change(s). The oligonucleotides were hybridized to a denatured circular plasmid and extended using Pfu polymerase (25). The reaction was repeated 12 times. For each mutant, an AccI fragment containing the mutation was transferred from pGEM1X2 to pGEM1F.

For transfection of mammalian cells, the cDNAs described above were transferred to the EcoRI site of the vector pCMV5 (26), which contains the cytomegalovirus promoter, a polyadenylation signal, and the SV40 origin of replication. A similar eukaryotic expression vector with a cDNA containing exons 1, 2, and 4-12 of mdm2 (pCOCD) was obtained from Moshe Oren. The cDNAs encoding F, X2, and D mRNAs (19) were isolated from a testis cDNA library.2

Transcription and Translation-- For transcription and translation in vitro, 1 µg of each cDNA was linearized and added to the transcription extract (Stratagene). RNAs were incubated with rabbit reticulocyte lysate (Stratagene) in the presence or absence of [35S]methionine (Amersham Pharmacia Biotech).

Transfections-- Calcium phosphate transfection of COS-1 cells was as described by Chu and Sharp (27). Cells were transfected in suspension, replated, and labeled with 50 µCi/ml [35S]Express (NEN Life Science Products) 48 h post-transfection.

Pulse-Chase Analysis-- C127 cells were radiolabeled for 0.5 h with [35S]Express and then rinsed with Dulbecco's modified Eagle's medium plus 10% fetal calf serum. For the chase periods, cells were incubated in Dulbecco's modified Eagle's medium, 10% fetal calf serum, and a 5-fold excess of unlabeled methionine. Lysates were made and normalized for total cell protein using the Bio-Rad protein assay. MDM2 was immunoprecipitated as described below.

Antibodies and Immunoprecipitation-- The monoclonal antibodies that recognized MDM2 were raised against human MDM2: 4B2, 3G5, 4B11, and 2A10 (28). For most experiments, MDM2 and p53 were immunoprecipitated as described previously (29) with the antibodies indicated in the figure legends. CM5 (Vector Labs, Inc.) is a p53-specific polyclonal antiserum whose epitopes do not overlap with those of antibody 421 (30).

Western Analysis-- Proteins were transferred to nitrocellulose (Hybond-ECL). The membranes were blocked overnight in 5% nonfat dry milk in Tris-buffered saline and 0.5% Igepal-CA 630 (Sigma). MDM2 proteins were detected using hybridoma supernatant containing the 2A10 antibody (diluted 1:50 in 5% milk) followed by sheep anti-mouse Ig conjugated to horseradish peroxidase (1:500 in 5% milk; Amersham Pharmacia Biotech). Immunoreactive proteins were revealed by ECL (Amersham Pharmacia Biotech) following the manufacturer's suggestions.

RT-PCR-- RNA was isolated using Tri Reagent (Molecular Research Center, Inc.). Five µg of total RNA was reverse-transcribed using oligo(dT) (Promega) as a primer, and the cDNA product of this reaction was amplified by PCR. The amount of cDNA added to each PCR was normalized using glyceraldehyde-3-phosphate dehydrogenase cDNA as the standard. Glyceraldehyde-3-phosphate dehydrogenase amounts were measured by limited PCR using the primer pair 5'-ACCACAGTCCATGCCATCACA and 5'-TCCACCACCCTGTTGCTGTA. Two primer sets were used to amplify mdm2. One set amplifies only RNAs initiated at the constitutive promoter, and the second set amplifies RNAs initiated at both the constitutive and p53-responsive promoters. A backward primer complementary to mdm2 exon 4 (5'-GCTCCAACGGACTTTAACAACTTC) was end-labeled with [gamma -32P]ATP using T4 kinase (New England Biolabs Inc.). This primer was paired with either a primer in exon 1 (5'-CGTGAAGGGTCGGAAGATGC) or a primer in exon 2 (5'-TGGGCGAGCGGGAGACCGAC) in PCRs using Taq polymerase. DNAs were amplified for 25 cycles (94 °C for 30 s, 59 °C for 30 s, and 72 °C for 45 s), which was determined to be within the exponential range of amplification of mdm2 in these samples. To quantify the different mdm2 transcripts, several reactions were performed in the presence of increasing amounts of an engineered internal standard (31). This standard contained sequences complementary to the primer pairs used and was amplified with efficiencies similar to those of the mdm2 cDNAs. The source for the standard was an mdm2 cDNA lacking exon 3 isolated from C127 cells following amplification of first-strand cDNA with a primer in exon 1 (5'-AGCCGCCGCCTTCTCGTC) and a primer that spans the junction of exons 4 and 5 (5'-TAATCTCTTGATAGTGTAAGTG). The PCR product was cloned using the Topo TA kit (Invitrogen) and sequenced. The internal standard was created by amplifying exons 1-4 of this mdm2 clone using a backward primer containing an insertion of 20 random base pairs (shown in boldface; 5'-GCTCCAACGGACTTTAACAACTTCCTCTACCAGTCAGCTATCCAAAAAGCAATG). Following amplification of cDNAs from untreated and UV-irradiated C127 cells, the products were separated on 5% nondenaturing polyacrylamide gels and quantified on a PhosphorImager (Molecular Dynamics, Inc.). To determine the amount of each mdm2 transcript, the logarithm of the amount of the internal standard was plotted against the logarithm of the ratio of the internal standard to the mdm2 transcript (31). When the ratio is 1, the log of the ratio is zero, and the amount of transcript is equal to the amount of standard. From the known quantity of the standard, the amount of each transcript was calculated.

    RESULTS

Two MDM2 Proteins Are Present in Mouse Embryo Fibroblasts-- DM3T3 cells, which are transformed and contain multiple copies of the mdm2 gene (32), express multiple proteins that react with antibodies to MDM2 (17). We compared the number of immunoreactive proteins in DM3T3 cells with wild-type MEFs, p53-null MEFs, and p53/mdm2-null MEFs (Fig. 1). Both DM3T3 cells and wild-type MEFs expressed at least four proteins that immunoreacted with the 2A10 monoclonal antibody. All four of these proteins were also evident in p53-null embryo fibroblasts, but only two appeared in p53/mdm2-null fibroblasts. Therefore, two of the immunoreactive proteins in wild-type mouse embryo fibroblasts are products of the mdm2 gene. These same two proteins were over-represented in the lysate from DM3T3 cells. The larger MDM2 protein expressed in DM3T3 cells has previously been designated "p90," whereas the smaller has been referred to as "p76" (17, 33). Our result indicates that both p90 and p76 arise from normal alleles of the mdm2 gene.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   Two MDM2 proteins are made in wild-type MEFs. A lysate from a cell line containing amplified mdm2 (DM3T3) was compared with lysates from three cell strains of different genotypes using Western analysis with MDM2 monoclonal antibody 2A10 and ECL. First lane, DM3T3 (20 µg); second lane, wild-type (WT) mouse embryo fibroblasts (150 µg); third lane, p53-null fibroblasts (150 µg); fourth lane, p53/mdm2-null fibroblasts (150 µg). The MDM2 proteins in the p53-null cells are marked by asterisks.

Synthesis of Two MDM2 Proteins Is Induced by UV Light-- Previously, we showed that exposure of the C127 murine cell line to UV light results in a p53-dependent increase in mdm2 expression (29, 34). Western blot analysis with a polyclonal antiserum indicated that expression of two immunoreactive proteins was increased (34). To determine whether the smaller protein induced by UV light was similar to the p76 protein expressed in DM3T3 cells, we compared the mobilities of the proteins in DM3T3 cells with those in C127 cells before and after UV light (Fig. 2). The major form of MDM2 induced in C127 cells migrated with p90 and the minor form with p76. Both proteins were expressed in cells lacking p53 ((10)3), but neither protein was induced following exposure of these cells to UV light.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of two MDM2 proteins is induced in a p53-dependent manner in response to UV light. MDM2 proteins expressed in DM3T3 cells were compared with proteins induced by UV light. C127 cells expressing p53 and (10)3 cells lacking p53 were exposed to a UV dose of 0 or 4 J/m2 and harvested 2 h post-irradiation. First lane, DM3T3 (15 µg); second lane, untreated C127 cells (175 µg); third lane, treated C127 cells (175 µg); fourth lane, untreated (10)3 cells (175 µg); fifth lane, treated (10)3 cells (175 µg). Proteins were separated by electrophoresis and analyzed by Western blotting as described in the legend to Fig. 1.

Pulse-chase analysis of C127 cells before and after UV light (Fig. 3) demonstrated that de novo synthesis of both p90 and p76 accounted for their increase in response to UV light. In the absence of UV light, the relative ratio of p90 to p76UV was ~4.0 (Fig. 3). Two h following exposure of C127 cells to a UV dose of 4 J/m2, the relative increase in p90 was 2.3-fold greater than that of p76UV, such that the ratio was 9.2. The p76UV protein does not appear to be a proteolytic product of p90 since it did not accumulate during the chase period (Fig. 3). Furthermore, both proteins have a half-life of ~10 min after exposure of cells to UV light. These data led us to conclude that the faster migrating protein, p76UV, was an MDM2 protein whose synthesis was induced by UV light.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   p90 and p76UV have similar half-lives. UV-treated and untreated C127 cells were labeled with [35S]Express for 30 min and then incubated for 0, 20, 40, or 80 min in medium containing an excess of unlabeled methionine. Equivalent amounts of total cell protein were immunoprecipitated twice sequentially with antibody 2A10. Following the first immunoprecipitation, the samples were boiled, cooled, diluted 2-fold with lysis buffer, adjusted to 2.6% Triton X-100, and reincubated with the 2A10 antibody and protein A-Sepharose.

Evidence That p76UV Lacks the N Terminus of p90-- To further characterize p76UV, we compared the mobility of p76UV to those of MDM2 proteins synthesized in rabbit reticulocyte lysates. mRNAs transcribed from the constitutive (P1) and p53-responsive (P2) promoters of mdm2 differed by the presence of exon 1, which is noncoding (Fig. 4A). Both mRNAs give rise to multiple proteins when translated in rabbit reticulocyte lysates (Fig. 4B) (19). The mechanism by which the multiple proteins are expressed is proposed to be internal initiation since multiple AUG codons exist in the mdm2 coding sequence, and none is in an optimal ribosome-binding sequence (20, 35). The proteins are postulated to be translated from AUGs 1 (and/or 6), 50, and 62 (19). Two of the proteins translated from each mRNA migrated with mobilities similar to those of the MDM2 proteins expressed in UV-treated C127 cells (Fig. 4B). The protein that migrates the same as p90 is thought to initiate at AUG 1 (and/or 6), and the protein that migrates the same as p76UV is thought to initiate at AUG 50 (19). p76UV also migrated with a protein synthesized from an mRNA, designated B, in which AUG 50 is the first start codon (Fig. 4B, compare lanes 3 and 4). The p76 protein in DM3T3 cells has been shown to lack the ability to bind p53, as has an exogenously expressed MDM2 protein lacking amino acids 1-49 of p90 (26). To test whether p76UV could co-immunoprecipitate with p53, we used two different p53-specific antibodies whose epitopes do not overlap (Fig. 4B). Whereas p90 co-immunoprecipitated with p53 when either antibody was used, p76UV did not co-immunoprecipitate with p53 (lanes 5 and 6). These results indicate that p76UV may lack the N terminus of p90 since the p53-binding site is at the N terminus of MDM2 (28).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Evidence that p76UV lacks the N terminus of p90. A, schematic of ATG codons within the first six exons of mdm2. Potential initiation codons for p76UV are in exons 4-6 of mdm2. B, p76UV does not bind p53. C127 cells were exposed to a UV dose of 4 J/m2 and harvested 2 h later. A lysate was incubated with MDM2 antibody 2A10 or p53 antibodies 421 and CM5, and the resulting immunoprecipitates were analyzed by Western blotting as described in the legend to Fig. 1. Lane 1, products of in vitro translation of mdm2 RNA containing exons 1-12 (F); lane 2, products of in vitro translation of mdm2 RNA lacking exon 1 (X2); lane 3, products of in vitro translation of mdm2 RNA lacking AUGs 1 and 6 (B); lane 4, products of immunoprecipitation of C127 cell lysate (100 µg) with MDM2 antibody 2A10; lane 5, products of immunoprecipitation of C127 cell lysate (1.5 mg) with p53 antibody 421; lane 6, products of immunoprecipitation of C127 cell lysate (1.5 mg) with p53 antibody CM5.

The epitopes of several monoclonal antibodies raised against human MDM2 have been determined (Fig. 5A) (28). Since the sequences of the human and murine MDM2 proteins are highly conserved, we used these antibodies to determine the domains of MDM2 present in p76. Monoclonal antibody 4B2 requires amino acids 19-50 of human MDM2 for binding (17, 28). The 4B2 antibody recognized murine p90, but not p76UV (Fig. 5B), indicating that p76UV lacks N-terminal sequences that contribute to binding by 4B2. A monoclonal antibody (3G5) with an epitope between amino acids 59 and 89 of human MDM2 recognized both p90 and p76UV, as did two monoclonal antibodies (2A10 and 4B11) that recognized epitopes in the middle (amino acids 294-339) and C-terminal (amino acids 383-491) portions of human MDM2, respectively (Fig. 5B). These results indicate that p76UV lacks the N terminus of p90.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 5.   Epitope analysis of murine p90 and 76UV. A, schematic of the epitopes for four monoclonal antibodies on human MDM2: 4B2, amino acids 19-50; 3G5, amino acids 59-89; 2A10, amino acids 294-339; and 4B11, amino acids 383-491 (28). B, immunoprecipitation (IP) of p90 and p76UV with MDM2 antibodies 4B2, 3G5, 2A10, and 4B11 followed by Western analysis with 2A10 and ECL. To ensure equivalent immunoprecipitation of p90 with the different monoclonal antibodies, 4B2 was cross-linked to protein A-Sepharose at high pH (41), and 3G5 was purified and then precipitated using immobilized anti-mouse IgG (Calbiochem). Lane 1, MDM2 proteins expressed in a reticulocyte lysate from RNA lacking exon 1; lane 2, total C127 cell lysate (150 µg); lanes 3-6, products of immunoprecipitation of C127 cell lysate (1.5 mg) with 4B2, 3G5, 2A10, and 4B11, respectively; lane 7, total C127 cell lysate.

Translation of p76UV Appears to Initiate at AUG 50-- There are several potential AUG initiation codons that are conserved between mouse and human MDM2 at codons 1, 6, 50, 62, and 102 (3). Initiation of translation at either AUG 1 or 6 gives rise to a protein the size of p90 (19, 28). AUG codons at positions 50, 62, and 102 could serve as initiation codons for smaller MDM2 proteins that cannot bind p53. To identify the codon likely to serve as the initiation codon for p76UV, we compared the immunoreactivity of p76UV with that of MDM2 proteins synthesized in rabbit reticulocyte lysates (Fig. 6A). Labeling the reticulocyte lysate allowed resolution of the faster migrating species into two distinct bands (Fig. 6A). The slower migrating protein in the doublet (p76IVT) has been presumed to arise from AUG 50 (19), and the faster migrating protein in the doublet (p74IVT) has been presumed to initiate at AUG 62 (19). Thus, we asked whether any of the monoclonal antibodies used in Fig. 5B could distinguish between p76IVT and p74IVT (Fig. 6A). As expected, all the antibodies recognized p90. Only the 3G5 antibody distinguished between p76IVT and p74IVT (lane 4). In fact, the protein thought to initiate at AUG 50 (p76IVT) had identical immunoreactivity to p76UV. Neither p76IVT nor p76UV protein was precipitated by 4B2, but both were precipitated by 3G5, 2A10, and 4B11. The epitope for 3G5 on human MDM2 has been mapped to within amino acids 59 and 89, and leucine 66, tyrosine 67, and glutamine 69, which are conserved between murine and human MDM2, are part of the epitope for 3G5 (36). However, it is not known whether 3G5 would be expected to distinguish between proteins initiated at AUGs 50 and 62. The assumptions that p76IVT initiates at AUG 50 and that p74IVT initiates at AUG 62 had to be tested before the identity of p76UV could be known.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 6.   Epitope analysis of MDM2 proteins translated in reticulocyte lysates. A, an mdm2 RNA containing exon 1 (from pGEM1F) was translated, and the resulting proteins were immunoprecipitated (IP) with MDM2-specific antibodies 4B2, 3G5, 2A10, and 4B11 and with p53-specific antibody 421. Lane 1, 14C-labeled molecular weight markers; lane 2, total products of in vitro translation; lane 3, 4B2; lane 4, 3G5; lane 5, 2A10; lane 6, 4B11; lane 7, 421; lane 8, total products of in vitro translation of wild-type F RNA; lanes 9-11, products of translation of RNA with AUG 50 mutated to AUC, AUG 62 mutated to AUC, and AUGs 50 and 62 mutated to AUC, respectively. B, shown is a comparison of immunoreactivity of MDM2 proteins synthesized from wild-type RNA (IVT F), RNA mutated at AUG 50 (IVT F50), or RNA lacking AUGs 1 and 6 (IVT B). Lanes 1-4, same as in A; lane 5, 4B11; lanes 6-9, products of in vitro translation of RNA with AUG 50 mutated to AUC before (lane 6) and after (lanes 7-9) immunoprecipitation with the same antibodies; lanes 10-13, total products of translation of RNA lacking AUGs 1 and 6 before (lane 10) and after (lanes 11-13) immunoprecipitation with the same antibodies.

To determine whether the p76IVT and p74IVT proteins initiate from AUGs 50 and 62, respectively, we used site-directed mutagenesis to generate cDNAs in which the ATG codon at position 50, 62, or 50 and 62 was changed to ATC. The cDNAs contained exons 1-12 so that p90 would serve as an internal control for translation. The mutant cDNAs were transcribed, and the resulting mRNAs were translated in reticulocyte lysates. Translation of RNAs containing single mutations resulted in synthesis of p90 and two other proteins (Fig. 6A, lanes 9 and 10). Mutation of AUG 50 resulted in loss of the slower migrating protein in the doublet (p76IVT), but revealed a new protein with mobility intermediate between those of p76IVT and p74IVT (lane 9). Mutation of AUG 62 resulted in expression of proteins identical in mobility to those expressed from pGEM1F (lane 10). Mutation of both AUGs 50 and 62 resulted in loss of p76IVT, but not p74IVT (lane 11). The protein with identical immunoreactivity to p76UV (p76IVT) initiated at AUG 50 since p76IVT was lost upon mutation of AUG 50 alone and in combination with AUG 62 (lanes 9 and 11). The protein that did not bind to 3G5 (p74IVT) is not a product of internal initiation at AUG 50 or 62 since it was not lost upon mutagenesis. This protein may be the product of either degradation or translation from AUG 102. AUG 62 is not used as an initiation codon for p74IVT, but it is used for the protein of intermediate mobility between p76IVT and p74IVT because this protein is translated from RNA mutated at AUG 50, but not from RNA mutated at AUGs 50 and 62 (lanes 9 and 11). This protein does not appear to be translated from the wild-type RNA, indicating that "leaky scanning" gives rise to translation of this protein only in the lysate programmed with RNA containing AUC 50.

The results described above indicate that p74IVT is not initiated at AUG 62, so we have no evidence that 3G5 can distinguish between proteins initiated at AUGs 50 and 62. To determine whether the 3G5 antibody could distinguish between proteins initiated at AUGs 50 and 62, we immunoprecipitated proteins expressed from the mRNA designated F50 in which AUG 50 had been changed to AUC. This mRNA gave rise to a protein initiated at AUG 62. The presence of p90 acted as a control for the immunoprecipitations. As shown above, two proteins translated from wild-type RNA containing exon 1 (F) were recognized by 3G5: p90 and p76IVT (Fig. 6B, lane 4). The p90 protein was also recognized by 3G5 when AUG 50 was altered to AUC (F50) (lane 8), but the smaller MDM2 proteins were not recognized, even though they were more abundant than p90 in the lysate (lane 6). This result indicates that 3G5 does not recognize MDM2 initiated at AUG 62, which is present in this translation (lane 6). An MDM2 protein with the same apparent mobility as p76UV was synthesized from an mRNA in which AUG 50 is the first methionine (B) and was recognized by 3G5 (lane 12). Together, these mapping experiments indicate that the MDM2 protein initiated at AUG 50 is recognized by 3G5, whereas the one initiated at AUG 62 is not. Hence, it is likely that p76UV, which is recognized by 3G5 (Fig. 5B), initiates at AUG 50.

Both Alternative Splicing and Internal Initiation Can Give Rise to a Protein the Size of p76UV in Intact Cells-- There is strong evidence that internal initiation of mdm2 mRNAs gives rise to multiple MDM2 proteins in rabbit reticulocyte lysates, but it has not been determined whether internal initiation of mdm2 mRNAs occurs in cells. Smaller proteins could also arise through alternative splicing of exons 3-5 of mdm2 since any one of three AUG codons could become the first initiation codon (Fig. 4A) (37). Deletion of exon 3 alone would place AUG 50 as the first methionine, and RNAs lacking exon 3 have been detected in cells expressing multiple MDM2 proteins (20).

To determine whether full-length and alternately spliced mRNA species lacking exon 3 were capable of directing synthesis of a protein with mobility similar to that of p76 in intact cells, we transfected mammalian cDNA expression plasmids into cultured cells (27). The cDNAs encoded mRNA initiated at the P1 promoter (containing exons 1-12; F), mRNA initiated at the P2 promoter (containing exons 2-12; X2), alternatively spliced mRNA initiated at the P1 promoter (containing exons 1, 2, and 4-12; D), and an artificially engineered mRNA (lacking exons 1 and 2 and part of exon 3 such that AUG 50 is the first methionine; B). COS-1 cells were chosen because they contain SV40 large T-antigen, which will stimulate replication of the expression plasmids, which contain the SV40 origin of replication (24), ensuring high levels of expression of the MDM2 proteins. The two normally spliced mRNAs initiated at the P1 (F) and P2 (X2) promoters directed the synthesis of MDM2 proteins with mobility similar to those of p90 and p76 (Fig. 7). The ratio of p90 to p76 was greater when the mRNA (X2) lacked exon 1. In fact, very little p76 could be detected when the mRNA lacked exon 1. This pattern of expression differs from that in the reticulocyte lysate in that there is less p76 made in cells, relative to p90, when either the F or X2 mRNA is translated. The pattern is similar in that F mRNA gives rise to more p76 relative to p90 than does X2 mRNA. As expected, neither of the mRNAs lacking AUGs 1 and 6 gave rise to p90, but both gave rise to a protein the size of p76UV. These data indicate that both internal initiation and alternative splicing are mechanisms through which p76 can be expressed in cells.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 7.   Both internal initiation and alternative splicing can give rise to proteins with the same mobility as p76UV in cells. COS-1 cells were transfected with pCMV5 (no cDNA insert), pCMV5F (exons 1-12), pCMV5X2 (exons 2-12), pCMV5B (exons 3-12, less the first two AUG codons), or pCOCD (exons 1, 2, and 4-12). Cells were radiolabeled with [35S]Express 48 h post-transfection, and MDM2 proteins were immunoprecipitated with polyclonal antisera against MDM2 (antibody 628).

If internal initiation were the mechanism by which the p76 proteins were synthesized from the mRNAs containing AUGs 1 and 6, mutagenesis of AUGs 50 and 62 should alter the translation products. These mutations were introduced into the mammalian expression vector pCMV5F, and the resulting plasmids were introduced into COS-1 cells. MDM2 proteins were radiolabeled and isolated by immunoprecipitation (Fig. 8). The results are similar to those obtained using the rabbit reticulocyte lysate: p90 and p76 were translated from wild-type mRNA and from mRNA with AUG 62 mutated to AUC. Mutation of AUG 50 abrogated expression of p76, but resulted in expression of a protein with slightly faster mobility. Mutation of AUGs 50 and 62 eliminated synthesis of this protein, indicating that AUG 62 can act as an initiation codon when AUG 50 is mutated. The fastest migrating MDM2 protein, p74, was not altered by these mutations. These results show that p76 (and p74) MDM2 proteins can be synthesized via internal initiation in intact cells.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   AUGs 50 and 62 act as initiation codons for MDM2 in cells. COS-1 cells were transfected with pCMV5, pCMV5B, pCMV5F, and derivatives of pCMV5F containing mutations at AUG 50, 62, or 50 and 62. Cells were labeled, and MDM2 proteins were immunoprecipitated twice in succession with 2A10 as described in the legend to Fig. 3.

An Alternatively Spliced mdm2 mRNA Is Expressed in C127 Cells-- Previously, we showed that the most abundant mdm2 RNA in C127 cells is initiated at the P1 promoter and contains exon 3 (29). mRNA lacking exon 3 was not detected in RNA from C127 cells using primer extension with a radiolabeled primer complementary to exon 4.3 Since p76 is expressed in C127 cells in the absence of exposure to UV light, it seemed reasonable to hypothesize that internal initiation was the mechanism through which this protein was expressed in these cells. However, if an mRNA lacking exon 3 were expressed at levels undetectable by the primer extension assay, it might still be a source for the small amount of p76 made. To test whether unirradiated C127 cells expressed mdm2 mRNA lacking exon 3, we used RT-PCR to amplify cDNAs containing exons 1 and 4 of mdm2. Two species were cloned and sequenced. One contained exons 1-4; the other contained exons 1, 2, and 4.3 Therefore, both internal initiation and alternative splicing are possible mechanisms for expression of p76 in unirradiated C127 cells.

An Alternatively Spliced RNA Initiated at the Internal Promoter of mdm2 is Induced in Response to UV Light-- The normally spliced mdm2 mRNA induced by UV light (X2) is an inefficient template for translation of p76 (Fig. 7). Since p76 is induced in C127 cells by UV light, we investigated whether some of the transcripts initiated at the P2 promoter were spliced to lack exon 3. A sensitive, quantitative, radioactive RT-PCR assay was designed to detect RNAs containing and lacking exon 3. The amount of each mRNA was determined before (Fig. 9A) and after (Fig. 9B) exposure of C127 cells to UV light. Two sets of primers were used. One set, in exons 1 and 4, amplified only mRNAs containing exon 1 (initiated at the P1 promoter). The other set, in exons 2 and 4, amplified mRNAs initiating at both the P1 and P2 promoters. The primer in exon 4 was end-labeled, and reactions were performed with increasing amounts of an internal standard so that the amount of each mdm2 mRNA species could be quantified. By subtracting the amount of mRNA initiated from the P1 promoter from the total, the amount of mRNA transcribed from the P2 promoter could be calculated. In untreated C127 cells (Fig. 9A), most of the mdm2 mRNA initiated at the P1 promoter and contained exon 3. Twenty-five percent of the mRNA synthesized from the P1 promoter was alternatively spliced and lacked exon 3. Little normally spliced or alternatively spliced mRNA was expressed from the P2 promoter in the absence of DNA damage. Two h following exposure to a dose of UV light of 4 J/m2, there was no change in the amount of either RNA initiated from the P1 promoter (Fig. 9B). However, the amount of mRNA transcribed from the P2 promoter and containing exon 3 was increased 14-fold. At the same time, the amount of mRNA initiated from the P2 promoter and lacking exon 3 was increased 3-fold. These results indicate that some or all of the increase in p76UV expression following exposure to UV light is mediated by alternative splicing of an induced RNA.


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 9.   An mdm2 transcript lacking exon 3 is induced by UV light. A, RT-PCR of mRNAs from C127 cells that had not been treated with UV light. RNA from C127 cells was reverse-transcribed into cDNA and amplified by PCR. For quantitation, an internal standard was included in the PCRs. Primer pairs in exons 1 and 4 (left) or exons 2 and 4 (right) were used as described under "Experimental Procedures" to reveal transcripts from the P1 promoter of mdm2 (left) and both the P1 and P2 promoters of mdm2 (right). Both sets of primers amplified cDNAs containing exon 3 (Ex 3 (+)) and lacking exon 3 (Ex 3 (-)). B, RT-PCR of mRNAs from C127 cells exposed to a UV dose of 4 J/m2 and harvested 2 h later. RNA was isolated and treated as described above.


    DISCUSSION

We have shown here that the p76 MDM2 protein is synthesized in normal cells. Alternatively spliced mdm2 mRNAs lacking exon 3 express p76, but not p90, and such mRNAs are induced by UV light. Synthesis of p76 is initiated at an AUG codon at position 50 of the coding sequence for p90, and p76 lacks the N-terminal domain required for interaction with p53. However, the protein retains many of the structural motifs of p90, including the nuclear localization signal, nuclear export signals, acidic domain (20), and RING finger (38). It is likely that p76 shares some functions with p90, and its presence in normal cells indicates that it may mediate some of the physiological functions of MDM2.

The ability of MDM2 to stimulate the degradation of p53 requires that MDM2 bind p53 (10, 11). However, the level of p76 may influence the stability of p53 because p76 could bind factors that regulate the process. For example, p76 binds the p19ARF protein, which inhibits the ability of p90 to stimulate degradation of p53 (13). An increase in the amount of p76 relative to p90 might free p90 to be more effective at stimulating degradation of p53. Alternatively, it is possible that p76 is a dominant-negative inhibitor of the ability of p90 to stimulate degradation of p53 since p76 might titrate factors required for that function of p90. We have preliminary evidence that the second model is correct. Overexpression of p76 antagonizes the decrease in p53 levels mediated by p90.4 Therefore, regulation of the relative amounts of p76 and p90 MDM2 may be an important mediator of p53 levels.

The ratio of p90 to p76 protein is determined, at least in part, by the ratio of the four different mdm2 mRNAs described here. The most abundant mdm2 mRNA in unstressed C127 cells is expressed from the P1 promoter and contains exon 3. This mRNA gives rise to p90 predominantly. Our RT-PCR analysis indicated that mdm2 mRNAs lacking exon 3 account for 25% of the total mdm2 mRNA in unstressed C127 cells. Such mRNAs give rise to p76 only. The results of the transfection experiments indicate that mRNAs lacking exon 3 may be up to five times more efficient at giving rise to p76 than are normally spliced mRNAs, if equal transfection efficiencies and RNA stabilities are assumed. If this number is valid, then more than half of the p76 present in C127 cells arises from alternatively spliced mRNA. These observations indicate that the ratio of normally spliced mRNA to alternatively spliced mRNA affects the ratio of p90 to p76. Indeed, 2 h following exposure to a dose of UV light of 4 J/m2, C127 cells have a higher ratio of p90 to p76, in part because there is more normally spliced mRNA relative to alternatively spliced mRNA than in the absence of exposure. In addition, the induced transcript is more efficient than the constitutive transcript at giving rise to p90 relative to p76. Under these same conditions, p53 levels are high, and the p53 protein is active as a transcriptional activator (29). Later in the UV response, p53 levels return to normal. The relative ratio of p76 to p90 may change throughout the UV response and determine whether p53 is stable. Since p53 stimulates apoptosis in response to UV light (39), its levels may be critical determinants of cell survival.

Dissection of the functions of p76 may reveal p53-independent functions of MDM2. For example, p76 retains the recently identified HECT domain, which is required for the ubiquitin ligase activity of MDM2 (40). Perhaps p76 targets a protein other than p53 for degradation. Evidence suggests that some of the oncogenic effects of MDM2 are mediated by mechanisms independent of p53 (4, 14, 15). In a subset of human tumors, multiple MDM2 proteins are overexpressed (7, 18). The human gene has AUG codons at positions 1, 6, 50, 62, and 102 (3), and a human p76 protein is expressed in normal fibroblasts.4 It may be that p76 is overexpressed in tumors and contributes to development of cancer. Identification of any oncogenic properties of p76 is important because therapeutic interventions are being designed to disrupt the interaction between p90 and p53. In tumors overexpressing p76, such therapies may not be effective.

    ACKNOWLEDGEMENTS

We thank Moshe Oren for mdm2 cDNA constructs; Arnold J. Levine for monoclonal antibodies to p53, MDM2, and T-antigen; Angie Teresky for wild-type mouse embryo fibroblasts; Guillermina Lozano for p53-null and p53/mdm2-null mouse fibroblasts; and Bill Sugden for COS-1 cells. The technical expertise of Marisa Holubar and Amy Prevost is greatly appreciated. We gratefully acknowledge Nancy Thompson and Kit Nolan for advice on typing monoclonal antibodies and John Petrini for advice on site-directed mutagenesis. We appreciate stimulating conversations about this work with Marilyn Kozak, Moshe Oren, and Jeff Ross and insightful comments on the manuscript by Chris Bradfield, Susan Mendrysa, and Jeff Ross.

    FOOTNOTES

* This work was supported in part by Cancer Center Support Grant CA-07175 (to the McArdle Laboratory for Cancer Research) and by National Institutes of Health Grant CA-70718 (to M. E. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by NCI Predoctoral Grant CA-09135 from the National Institutes of Health.

§ Supported by Predoctoral Grant GM-07215 from the National Institutes of Health.

To whom correspondence should be addressed: 207A McArdle Lab. for Cancer Research, 1400 University Ave., Madison, WI 53706. Tel.: 608-265-5537; Fax: 608-262-2824; E-mail: perry{at}oncology.wisc.edu.

2 M. Oren, personal communication.

3 L. J. Saucedo, unpublished results.

4 M. Holubar and M. E. Perry, unpublished results.

    ABBREVIATIONS

The abbreviations used are: MEFs, mouse embryo fibroblasts; RT-PCR, reverse transcription-polymerase chain reaction.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
REFERENCES
  1. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. (1995) Nature 378, 203-206[CrossRef][Medline] [Order article via Infotrieve]
  2. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. (1995) Nature 378, 206-208[CrossRef][Medline] [Order article via Infotrieve]
  3. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. (1992) Nature 358, 80-83[CrossRef][Medline] [Order article via Infotrieve]
  4. Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., and Finlay, C. A. (1997) Genes Dev. 11, 714-725[Abstract]
  5. Chen, C.-Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., and Kastan, M. B. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2684-2688[Abstract]
  6. Dubs-Poterszman, M.-C., Tocque, B., and Wasylyk, B. (1995) Oncogene 11, 2445-2449[Medline] [Order article via Infotrieve]
  7. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. (1993) Cancer Res. 53, 2231-2234[Abstract]
  8. Haupt, Y., Barak, Y., and Oren, M. (1996) EMBO J. 15, 1596-1606[Abstract]
  9. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) Cell 69, 1237-1245[Medline] [Order article via Infotrieve]
  10. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Nature 387, 296-299[CrossRef][Medline] [Order article via Infotrieve]
  11. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. (1997) Nature 387, 299-303[CrossRef][Medline] [Order article via Infotrieve]
  12. Zhang, Y., Xiong, Y., and Yarborough, W. G. (1998) Cell 92, 725-734[Medline] [Order article via Infotrieve]
  13. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., Cordon-Cardo, C., and DePinho, R. A. (1998) Cell 92, 713-723[Medline] [Order article via Infotrieve]
  14. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. (1995) Nature 375, 691-694[CrossRef][Medline] [Order article via Infotrieve]
  15. Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedl, N., Xing, J., Sellers, W. R., and Livingston, D. M. (1995) Nature 375, 694-698[CrossRef][Medline] [Order article via Infotrieve]
  16. Sigalis, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. (1996) Nat. Med. 2, 912-917[Medline] [Order article via Infotrieve]
  17. Olson, D. C., Marechal, V., Momand, J., Chen, J., Romocki, C., and Levine, A. J. (1993) Oncogene 8, 2353-2360[Medline] [Order article via Infotrieve]
  18. Landers, J. E., Haines, D. S., Strauss, J. F., and George, D. L. (1994) Oncogene 9, 2745-2750[Medline] [Order article via Infotrieve]
  19. Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. (1994) Genes Dev. 8, 1739-1749[Abstract]
  20. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. (1991) EMBO J. 10, 1565-1569[Abstract]
  21. McMasters, K. M., Montes de Oca Luna, R., Pena, J. R., and Lozano, G. (1996) Oncogene 13, 1731-1736[Medline] [Order article via Infotrieve]
  22. Sherley, J. L. (1991) J. Biol. Chem. 266, 24815-24828[Abstract/Free Full Text]
  23. Harvey, D. M., and Levine, A. J. (1991) Genes Dev. 5, 2375-2385[Abstract]
  24. Gluzman, Y. (1981) Cell 23, 175-182[Medline] [Order article via Infotrieve]
  25. Papworth, C., Bauer, J. C., Braman, J., and Wright, D. A. (1995) Strategies 9, 3-4
  26. Haines, D. S., Landers, J. E., Engle, L. J., and George, D. L. (1994) Mol. Cell. Biol. 14, 1171-1178[Abstract]
  27. Chu, G., and Sharp, P. A. (1981) Gene (Amst.) 13, 197-202[CrossRef][Medline] [Order article via Infotrieve]
  28. Chen, J., Marechal, V., and Levine, A. J. (1993) Mol. Cell. Biol. 13, 4107-4114[Abstract]
  29. Saucedo, L. J., Carstens, B. C., Seavey, S. E., Albee, L. D., and Perry, M. E. (1998) Cell Growth Differ. 9, 119-130[Abstract]
  30. Lane, D. P., Stephen, C. W., Midgley, C. A., Sparks, A., Hupp, T. R., Daniels, D. A., Greaves, R., Reid, A., Vojtesek, B., and Picksley, S. M. (1996) Oncogene 12, 2461-2466[Medline] [Order article via Infotrieve]
  31. Kirchmaier, A., and Sugden, B. (1998) J. Virol. 72, 1766-1775
  32. Cahilly Snyder, L., Yang-Feng, T., Francke, U., and George, D. L. (1987) Somatic Cell Mol. Genet. 13, 235-244[Medline] [Order article via Infotrieve]
  33. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., and Levine, A. J. (1990) Cell Growth Differ. 1, 571-580[Abstract]
  34. Perry, M. E., Piette, J., Zawadski, J. A., Harvey, D., and Levine, A. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11623-11627[Abstract]
  35. Kozak, M. (1984) Nature 308, 241-246[Medline] [Order article via Infotrieve]
  36. Bottger, A., Bottger, V., Garcia-Echeverria, C., Chene, P., Hochkeppel, H.-K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., and Lane, D. P. (1997) J. Mol. Biol. 269, 744-756[CrossRef][Medline] [Order article via Infotrieve]
  37. Montes de Oca Luna, R., Tabor, A. D., Eberspaecher, H., Hulboy, D. L., Worth, L. L., Coleman, M. S., Finlay, C. A., and Lozano, G. (1996) Genomics 33, 352-357[CrossRef][Medline] [Order article via Infotrieve]
  38. Boddy, M. N., Freemont, P. S., and Borden, K. L. B. (1994) Trends Biochem. Sci. 19, 198-199[CrossRef][Medline] [Order article via Infotrieve]
  39. Zeigler, A., Jonason, A. S., Lefell, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., and Brash, D. E. (1994) Nature 372, 773-776[CrossRef][Medline] [Order article via Infotrieve]
  40. Honda, R., Tanaka, H., and Yasuda, H. (1997) FEBS Lett. 420, 25-27[CrossRef][Medline] [Order article via Infotrieve]
  41. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.